US › Healthcare

iSpecimen Inc (ISPC)

US · Healthcare · Diagnostics & Research

$1.35-1.46%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$151,940

Revenue YoY

-78.7%

Net profit

$-1.4M

EPS

$-0.98

Net margin

-896.9%

Key statistics

Market cap

$3.7M

Forward P/E

0.0

P/B

2.18

Book value

$1.14

EPS (TTM)

$-49.81

52-week high

$86.40

52-week low

$1.38

50-day MA

$2.05

200-day MA

$7.50

Beta

1.62

Analyst view

Analysts rate iSpecimen Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders

0.04%

Institutions

2.58%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.31%
Jane Street Group LLC	0.06%
UBS Group AG	0.05%
Citadel Advisors Llc	0.05%
Tower Research Capital LLC	0.01%
BlackRock Inc	0.00%
SBI Securities Co Ltd	0.00%
Susquehanna International Group, LLP	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for iSpecimen Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.